Identifying more sensitive biomarker tests for Alzheimer’s Disease (AD) is an unmet medical need. It is key in the global efforts to validate disease-modifying AD therapeutics and identify appropriate recipients in clinical trials once more therapies are approved. Fluid biomarkers are the most attractive tests for AD. However, there are challenges in developing blood biomarkers for neurological disease with specificity precision, and reproducibility.
In this webinar, our expert speaker, Professor Lei Liu, Assistant Professor of Neurology from Harvard Medical School will discuss strategies in developing an ultrasensitive immunoassay* to measure oligomeric amyloid β in human plasma precisely.
- Explore some of the most exciting research advancing our understanding of neurodegenerative disease
- Discover the challenges and opportunities behind developing blood biomarkers for neurological diseases
- Interact with Professor Liu through a Q&A session following the webinar
*For Research Use Only. Not for use in diagnostic procedures.